Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patientsDaniel Whittam, Brigitte Wildemann, Klaus Berek et al.|Multiple Sclerosis and Related Disorders|2020Cited by 179
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Éric Berger, Mathilde Lefort et al.|CNS Drugs|2021Cited by 12
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisMathilde Lefort, F. Grand’Maison, Sifat Sharmin et al.|BMC Medical Research Methodology|2022Cited by 6
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data NetworkJohannes Lorscheider, Alessio Signori, Suvitha Subramaniam et al.|Journal of Neurology Neurosurgery & Psychiatry|2024Cited by 4